Bayer's Crop Science Bets on a Decade of Blockbusters as Kerendia Wins Wider FDA Label
Published on 09/19/2026 at 19:41 | Editorial boerse-global.de
Bayer shareholders are being asked to weigh two very different clocks. One is the regulatory calendar, where progress can arrive in a single afternoon. The other is the agricultural development cycle, where the payoff from today's research may not surface until the 2030s. Both were ticking last week.
On the pharmaceutical side, US authorities cleared Kerendia for the treatment of adults with chronic kidney disease and type 1 diabetes, widening the label of a drug that had already been on the market. The decision, announced Thursday, hands the Leverkusen group a broader commercial runway in a franchise where treatment options have historically been thin.
Over in Crop Science, management used an investor day earlier in the month to sketch out its ambitions for the coming decade: ten blockbuster products launched within ten years, each carrying a peak sales threshold of at least EUR 500 million. Hitting that bar is the yardstick by which the division's organic growth will be judged.
CropKey and the Push to Industrialize Discovery
Underpinning the target is a bet on speed. Bayer intends to lean on CropKey, its AI-driven discovery platform, to identify future active ingredients far more efficiently than conventional screening allows. Two products from the new generation are already in the field. The Preceon Smart Corn System and the insecticide Plenexos are commercially deployed, with Preceon available in Mexico, Italy, Spain and the United States.
The spending discipline accompanying that push is starting to show. Bayer has booked close to EUR 400 million in cost reductions across the division so far, according to company figures — a figure that gives the innovation program some breathing room as research intensity stays high.
Should investors sell immediately? Or is it worth buying Bayer?
The European Bottleneck
The bullish case runs into a stubborn obstacle on Bayer's home continent. The heaviest commercial impact from the new agricultural technologies is not expected in Europe until 2030 to 2035, a lag that carries unusual weight because conventional crop protection accounts for roughly 70% of Bayer's European sales.
Should approval processes stall in core markets, or should tighter regulation curb the use of modern seed technologies, the projected EUR 500 million peak per product starts to look fragile rather than assured. That timing mismatch — near-term costs against distant revenue — is the crux of the bearish reading.
Roundup Settlement Still Casts a Long Shadow
Meanwhile, the legal overhang from the Monsanto acquisition continues to shape how the market prices Bayer. A settlement worth USD 7.25 billion could resolve tens of thousands of claims tied to the glyphosate-based weedkiller Roundup, with Bayer exposed through its Monsanto subsidiary. The final enforceability of such settlement structures will determine how much financial latitude the group retains, and the litigation has repeatedly cooled investor appetite.
The shares reflected that caution on the last trading day of the week. Bayer closed Friday at EUR 47.96, down 2.3%, with no fresh catalyst identified for the pullback. Even after that slip, the stock is up 30% since the start of the year.
Chart watchers have taken note of the retreat: the price has fallen below its 50-day moving average of EUR 48.39, a signal that short-term oriented investors are turning careful. A failure to reclaim key resistance levels could add pressure if product launches slip beyond schedule.
A Buy Rating and a Governance Filing
Analysts have been more constructive than the tape. Deutsche Bank Research reaffirmed its Buy rating on the DAX constituent on September 10, keeping its price target unchanged at EUR 60. The endorsement rests on the gradual effect of the savings program and the new products in Bayer's core divisions.
Bayer at a turning point? This analysis reveals what investors need to know now.
Separately, Bayer published a voting rights notification under German securities trading law on Friday, a routine disclosure that nonetheless drew attention amid the week's heavier news flow.
What Investors Are Actually Watching
The setup leaves shareholders with a clear framework. As long as the stock defends its broader recovery level and tangible progress on new approvals continues, the upside case holds. Reclaiming the moving averages quickly would put a continuation of the rebound back within reach. A sustained stay below those lines, by contrast, would extend the consolidation and push the market to focus again on the long payback periods attached to Bayer's research spending.
The next hard datapoint for the agricultural division lands next year, when the commercial launch of the first of the new generation gets underway. That debut should offer the earliest concrete evidence of whether Crop Science's ten-year plan can survive contact with the market.
Ad
Bayer Stock: New Analysis - 19 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
